| Role of casein kinase 1A1 in the biology and targeted therapy of del (5q) MDS RK Schneider, V Adema, D Heckl, M Järås, M Mallo, AM Lord, LP Chu, ... Cancer cell 26 (4), 509-520, 2014 | 202 | 2014 |
| Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms L Palomo, M Meggendorfer, S Hutter, S Twardziok, V Ademà, I Fuhrmann, ... Blood, The Journal of the American Society of Hematology 136 (16), 1851-1862, 2020 | 129 | 2020 |
| Personalized prediction model to risk stratify patients with myelodysplastic syndromes A Nazha, R Komrokji, M Meggendorfer, X Jia, N Radakovich, J Shreve, ... Journal of Clinical Oncology 39 (33), 3737, 2021 | 106 | 2021 |
| Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome D Valcárcel, V Adema, F Solé, M Ortega, B Nomdedeu, G Sanz, E Luño, ... J Clin Oncol 31 (7), 916-922, 2013 | 76 | 2013 |
| Consequences of mutant TET2 on clonality and subclonal hierarchy CM Hirsch, A Nazha, K Kneen, ME Abazeed, M Meggendorfer, ... Leukemia 32 (8), 1751-1761, 2018 | 64 | 2018 |
| Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes A Nazha, K Al-Issa, BK Hamilton, T Radivoyevitch, AT Gerds, S Mukherjee, ... Leukemia 31 (12), 2848-2850, 2017 | 64 | 2017 |
| Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes Y Nagata, S Narumi, Y Guan, BP Przychodzen, CM Hirsch, H Makishima, ... Blood, The Journal of the American Society of Hematology 132 (21), 2309-2313, 2018 | 54 | 2018 |
| A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient Cells in Myeloid Neoplasms Y Guan, AD Tiwari, JG Phillips, M Hasipek, DR Grabowski, S Pagliuca, ... Blood cancer discovery 2 (2), 146-161, 2021 | 45 | 2021 |
| Complex landscape of alternative splicing in myeloid neoplasms CE Hershberger, DC Moyer, V Adema, CM Kerr, W Walter, S Hutter, ... Leukemia 35 (4), 1108-1120, 2021 | 44 | 2021 |
| Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia H Awada, Y Nagata, A Goyal, MF Asad, B Patel, CM Hirsch, ... Blood advances 3 (3), 339-349, 2019 | 40 | 2019 |
| Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide E Negoro, T Radivoyevitch, C Polprasert, V Adema, N Hosono, ... Leukemia 30 (12), 2405-2409, 2016 | 40 | 2016 |
| Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome J Durrani, H Awada, A Kishtagari, V Visconte, C Kerr, V Adema, Y Nagata, ... Leukemia 34 (3), 957-962, 2020 | 35 | 2020 |
| Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy I Ganan-Gomez, H Yang, F Ma, G Montalban-Bravo, N Thongon, ... Nature medicine 28 (3), 557-567, 2022 | 34 | 2022 |
| Distinct clinical and biological implications of CUX1 in myeloid neoplasms M Aly, ZM Ramdzan, Y Nagata, SK Balasubramanian, N Hosono, ... Blood advances 3 (14), 2164-2178, 2019 | 34 | 2019 |
| Subclonal STAT3 mutations solidify clonal dominance CM Kerr, MJ Clemente, PW Chomczynski, B Przychodzen, Y Nagata, ... Blood advances 3 (6), 917-921, 2019 | 33 | 2019 |
| Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features L Palomo, O Garcia, M Arnan, B Xicoy, F Fuster, M Cabezón, R Coll, ... Oncotarget 7 (35), 57021, 2016 | 31 | 2016 |
| Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: Does− 7/7q− detection by FISH have prognostic value? V Ademà, JM Hernández, M Abáigar, E Lumbreras, E Such, A Calull, ... Leukemia research 37 (4), 416-421, 2013 | 27 | 2013 |
| A personalized prediction model to risk stratify patients with myelodysplastic syndromes A Nazha, RS Komrokji, M Meggendorfer, S Mukherjee, N Al Ali, W Walter, ... Blood 132, 793, 2018 | 23 | 2018 |
| Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases L Palomo, B Xicoy, O Garcia, M Mallo, V Ademà, M Cabezón, M Arnan, ... American journal of hematology 91 (2), 185-192, 2016 | 23 | 2016 |
| BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes N Abuhadra, S Mukherjee, K Al-Issa, V Adema, CM Hirsch, A Advani, ... Leukemia & lymphoma 60 (6), 1587-1590, 2019 | 22 | 2019 |
